The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...

They’ve studied and administered it in controlled, clinical settings to help with treatment-resistant depression and other conditions. Esketamine may be an option for people with major ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

MDD has a high economic burden, with nearly half of it attributable to treatment-resistant depression (TRD). 3,4,5 "Treatment-resistant depression can be very complicated, especially for patients ...

Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral ...